To understand the potential of AgNPs as therapeutic agents that potentiate the effect of current standard treatment approved for ccRCC, we studied their combined effect with Everolimus, an mTOR pathway inhibitor used as a second-line and third-line treatment in ccRCC [12]. The gene discussed is MTOR; the disease is nonpapillary renal cell carcinoma.